Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,511.00-0.52%ETH$2,696.35-0.71%GOLD$4,192.90+0.14%OIL$89.86+0.47%
Smart Investors Daily
SID Premium
CB

NASDAQ · CBIO

Crescent Biopharma, Inc. Common Stock

Healthcare · Biotechnology

$13.94

Down-$0.37 (-2.65%)

Updated Oct 6, 2026, 11:28 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
213.67M
P/E ratio
-45.46
Dividend yield
0.00%
52-week range
$8.72 – $27.41
Volume
187.01K
Avg. volume
143.92K

Price performance · CBIO

CBIO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CBIO closed at $13.94 after 20 trading sessions, down 31.87% for the selected period.

Last close
$13.94
Period change
-31.87%
Period low
$13.94
Period high
$20.46
Daily close
View OHLC price history
CBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$14.42$14.42$13.63$13.94187.01K
Oct 2, 2026$14.48$14.55$14.07$14.32283.27K
Oct 1, 2026$14.61$14.73$14.10$14.26300.91K
Sep 30, 2026$14.89$15.00$14.23$14.59289.53K
Sep 29, 2026$14.66$15.62$14.16$14.76684.62K
Sep 28, 2026$13.93$14.755$13.50$14.53294.76K
Sep 25, 2026$14.29$14.46$13.66$13.99228.69K
Sep 24, 2026$14.04$14.48$13.44$14.24568.82K
Sep 23, 2026$16.37$16.465$13.70$14.19727.68K
Sep 22, 2026$16.48$16.645$16.01$16.44257.62K
Sep 21, 2026$16.93$17.035$15.76$16.25375.78K
Sep 18, 2026$16.67$17.87$16.15$16.893.12M
Sep 17, 2026$17.60$18.565$16.32$16.77665.9K
Sep 16, 2026$18.87$19.26$17.09$17.18528.91K
Sep 15, 2026$19.60$20.305$18.40$18.80357.96K
Sep 14, 2026$19.50$20.40$19.40$19.68251.18K
Sep 11, 2026$19.81$20.35$19.11$19.41264.45K
Sep 10, 2026$19.65$19.895$19.16$19.46233.14K
Sep 9, 2026$20.30$20.91$19.92$19.99296.01K
Sep 8, 2026$20.58$21.19$19.91$20.46647.21K

Latest CBIO news

The latest Smart Investors Daily articles mentioning CBIO.

Stock researchCompany · Overview

CBIO research

Overview

Company profile and research snapshot.

Company profile

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.00
Implied upside
—
Analysts
—
CBIO recent ratings
DateFirmRatingTarget
Sep 14, 2026WedbushOutperform—
Aug 27, 2026WedbushOutperform—
Jun 1, 2026HC Wainwright & Co.Neutral—
Mar 2, 2026HC Wainwright & Co.Buy—
Jan 21, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Crescent Biopharma Announces Grants of Inducement Awards

WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 31,200 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By